Soru

Zorluk: ZorCardiovascular System

A 34-year-old man with a history of intravenous opioid use disorder is hospitalized for a 1-week history of fever, chills, and pleuritic chest pain. On admission, multiple sets of blood cultures are drawn, and empiric intravenous vancomycin and cefepime are initiated. A transthoracic echocardiogram reveals a 1.4-cm1.4\text{-cm} mobile vegetation on the tricuspid valve with moderate tricuspid regurgitation. Two days later, all blood culture bottles grow *Staphylococcus aureus*. Susceptibility testing indicates the isolate is resistant to penicillin G, but susceptible to oxacillin, cefazolin, and vancomycin. The patient's medical record notes a history of a diffuse maculopapular rash after taking amoxicillin for a respiratory infection 5 years ago; he specifically denies any history of facial swelling, difficulty breathing, or anaphylaxis associated with medications. His temperature is currently 37.6∘C37.6^\circ\text{C} (99.7∘F99.7^\circ\text{F}), blood pressure is 122/76 mm Hg122/76\text{ mm Hg}, and heart rate is 82/min82/\text{min}. Which of the following is the most appropriate next step in the pharmacologic management of this patient?

  1. Discontinue vancomycin and cefepime, and initiate intravenous cefazolin.Cevap
  2. B
    Discontinue cefepime and continue intravenous vancomycin as monotherapy.
  3. C
    Discontinue vancomycin and cefepime, and initiate intravenous daptomycin.
  4. D
    Continue intravenous vancomycin and cefepime for a total of 6 weeks.
  5. E
    Discontinue cefepime, continue intravenous vancomycin, and add intravenous gentamicin.

Cevap

Discontinue vancomycin and cefepime, and initiate intravenous cefazolin.
The correct answer is to discontinue vancomycin and cefepime, and initiate intravenous cefazolin. This patient has right-sided native valve infective endocarditis caused by methicillin-susceptible *Staphylococcus aureus* (MSSA), as proven by the isolate's susceptibility to oxacillin. For MSSA bacteremia and endocarditis, definitive, targeted therapy with a beta-lactam antibiotic (such as cefazolin, nafcillin, or oxacillin) is vastly superior to vancomycin, demonstrating more rapid bacterial clearance, lower rates of relapse, and reduced overall mortality. Although the patient has a reported penicillin allergy, his reaction (a delayed maculopapular rash) was non-severe and not IgE-mediated (i.e., no anaphylaxis, angioedema, or bronchospasm). First-generation cephalosporins like cefazolin have a distinct side-chain structure and a negligible risk of cross-reactivity in patients with non-anaphylactic penicillin allergies, making them extremely safe and highly preferred in this scenario. De-escalating from broad-spectrum empiric therapy strictly aligns with the core principles of antibiotic stewardship.

Adım Adım Çözüm

1
Identify the causative organism and its resistance profile from the blood culture data.
The blood cultures grew Staphylococcus aureus that is susceptible to oxacillin, confirming it is methicillin-susceptible S. aureus (MSSA).
Accurate organism identification and susceptibility testing dictate the spectrum of definitive antibiotic therapy.
2
Evaluate the patient's penicillin allergy history.
The patient experienced a maculopapular rash to amoxicillin, which is a non-severe, non-IgE-mediated reaction.
The severity of the prior allergic reaction determines whether structurally related beta-lactam antibiotics can be safely administered.
3
Select the optimal definitive antibiotic therapy for MSSA infective endocarditis based on the patient's history.
Intravenous cefazolin is selected as the definitive treatment.
Beta-lactams are clinically superior to vancomycin for clearing MSSA. Cefazolin has negligible cross-reactivity and is the drug of choice for patients with non-anaphylactic penicillin allergies.

Anahtar Kavram

Definitive pharmacotherapy for methicillin-susceptible Staphylococcus aureus (MSSA) infective endocarditis.
Tahmini Süre:1m 30s
Bu soruyu puanla